GlassScriptPhysician profile
Mark H Christensen
NPI 1609161124
$30,960.10
in general payments reported to CMS, 2019-2025
14 companies · $72.14 in 2025
The $72.14 reported for 2025 was more than what a typical Emergency Medicine provider received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $260 · 2021: $8,925 · 2022: $14K · 2023: $7,036 · 2024: $119 · 2025: $72.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,750 · Food and Beverage: $477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,750.00 |
| Food and Beverage | $477.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainscope Company, INC. | $30,140.93 | 2020-2023 | Brainscope One |
| Mindray Ds USA, INC. | $167.61 | 2021-2023 | Te7 Max, Te X |
| Astrazeneca Pharmaceuticals LP | $130.38 | 2019-2024 | Andexxa |
| Mylan Specialty L.P. | $122.55 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $115.90 | 2019-2021 | |
| Abbott Laboratories | $103.72 | 2024 | Acculink |
| Portola Pharmaceuticals, LLC | $40.62 | 2019 | |
| Abbvie INC. | $39.32 | 2025 | |
| Btg International INC. | $24.20 | 2022 | |
| Purdue Pharma L.P. | $17.56 | 2025 | Nalmefene Hydrochloride |
| Biomerieux INC | $17.47 | 2023 | Filmarray Pneumonia Panel (Pneumo) |
| Currax Pharmaceuticals LLC | $15.26 | 2025 | Contrave |
| Novo Nordisk INC | $12.75 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Christensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.